Q-omics provides the consensus-scored KANSL2 profile across patient tissues and cancer cell-line models. KANSL2 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, KANSL2 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, KANSL2 protein abundance shows 20,645 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight ACC, HNSC, and GBM as cancer lineages where KANSL2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for KANSL2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes KANSL2 survival associations across molecular data types. KANSL2 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible KANSL2 RNA expression–survival associations across cancer types. High KANSL2 expression shows unfavorable associations in ACC, LIHC, UVM, KICH and LGG, but favorable associations in LUAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for KANSL2 RNA expression.
This table summarizes KANSL2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 6. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for KANSL2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. KANSL2 shows higher tumor expression in HNSC, COAD, LIHC, BLCA, KIRC and STAD. The HNSC box plot shows higher KANSL2 RNA expression in tumor versus normal tissue (log2 FC = +0.830, t-test p < 0.001).
This table shows molecular features associated with KANSL2 in patient tissues and cancer cell lines. In patient samples, KANSL2 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, KANSL2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and BLOOD_Leukemia.
